Physician profile
Samuel Johnson
NPI 1083638217
$7,570.91
in general payments reported to CMS, 2019-2025
26 companies · $1,778 in 2025
The $1,778 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $273 · 2021: $968 · 2022: $1,163 · 2023: $1,420 · 2024: $1,396 · 2025: $1,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,396 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,396.03 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,821.47 | 2019-2025 | |
| Janssen Biotech, INC. | $1,167.17 | 2019-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $756.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $646.41 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $428.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.56 | 2019-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $292.72 | 2023-2025 | Dupixent |
| Celgene Corporation | $248.97 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $239.97 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $207.98 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $184.87 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $169.38 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $167.28 | 2022-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $143.40 | 2021-2022 | |
| Madrigal Pharmaceuticals | $136.69 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $103.87 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $103.54 | 2019-2024 | Suflave, Sutab |
| Pfizer INC. | $94.19 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $65.35 | 2025 | Zenpep, Vowst |
| Redhill Biopharma INC. | $61.74 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $46.15 | 2024 | Voquezna |
| Celltrion USA INC. | $42.33 | 2024-2025 | Vegzelma |
| Allergan, INC. | $32.82 | 2019-2020 | |
| Alfasigma USA, INC. | $25.19 | 2020 | |
| Mauna Kea Technologies, INC. | $24.26 | 2024 | |
| Daiichi Sankyo INC. | $15.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.